Live Analyst Rating Changes 19795 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Patrick Wood
UBS

Patrick Wood

UBS
Wall Street Analyst
★☆☆☆☆
#2823
on 13Foresight · ranked by our own returns
42%
Success Rate
-2.4%
Average Return
36 of 85 calls profitable · -10.9% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 42% of Patrick Wood's ratings turned a profit when each position was held for 1 year — averaging -2.4% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

83 Buy 67 Hold 12 Sell
Patrick's Stock Coverage 53 ratings · 2026-08-07
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
PODD
Insulet
 Aug 06, 2026 HOLD Strong Buy
+61.2% avg upside
32 analysts
$150.00
9.32% Upside
 +0.0% ·
SOLV
Solventum Corporation
 Aug 06, 2026 BUY Strong Buy
+8.2% avg upside
16 analysts
$101.00
20.23% Upside
 +0.0% ·
RXST
RxSight
 Aug 06, 2026 HOLD Hold
+49.7% avg upside
13 analysts
$6.30
6.08% Upside
 +0.0% ·
SGHT
Sight Sciences
 Aug 06, 2026 BUY Strong Buy
+18.3% avg upside
13 analysts
$8.00
12.71% Upside
 +0.0% ·
ZBH
Zimmer Biomet Holdings
 Aug 06, 2026 BUY Buy
+16.2% avg upside
38 analysts
$120.00
23.84% Upside
 -0.7% ·
ATEC
Alphatec Holdings
 Aug 05, 2026 BUY Strong Buy
+80.0% avg upside
23 analysts
$16.00
76.31% Upside
 -3.8% ·
PRCT
PROCEPT BioRobotics
 Aug 05, 2026 HOLD Buy
+60.9% avg upside
17 analysts
$20.00
3.82% Upside
 +3.6% ·
TMDX
TransMedics Group
 Aug 05, 2026 HOLD Strong Buy
+35.8% avg upside
15 analysts
$77.00
1.35% Downside
 +9.7% ·
SIBN
SI-Bone
 Aug 04, 2026 BUY Strong Buy
+43.4% avg upside
18 analysts
$25.00
40.12% Upside
 +0.0% ·
GKOS
Glaukos
 Jul 30, 2026 HOLD Strong Buy
-2.8% avg upside
21 analysts
$172.00
1.30% Upside
 +4.9% ·
BLCO
Bausch + Lomb Corporation
 Jul 30, 2026 BUY Buy
+21.2% avg upside
19 analysts
$23.00
38.40% Upside
 -1.9% ·
BSX
Boston Scientific
 Jul 30, 2026 BUY Strong Buy
+38.2% avg upside
38 analysts
$67.00
34.21% Upside
 +7.2% ·
MDT
Medtronic
 Jul 28, 2026 BUY Buy
+12.1% avg upside
38 analysts
$100.00
15.87% Upside
 +0.3% ·
ABT
Abbott Laboratories
 Jul 28, 2026 BUY Strong Buy
+7.4% avg upside
36 analysts
$125.00
16.91% Upside
 +0.5% ·
BAX
Baxter International
 Jul 28, 2026 HOLD Buy
+21.7% avg upside
23 analysts
$25.00
9.71% Downside
 +10.8% ·
BDX
Becton Dickinson
 Jul 28, 2026 BUY Buy
+9.9% avg upside
25 analysts
$190.00
6.15% Upside
 +5.7% ·
ENOV
Enovis
 Jul 28, 2026 BUY Strong Buy
+151.8% avg upside
39 analysts
$51.00
82.22% Upside
 -3.4% ·
COO
Cooper Co
 Jul 28, 2026 HOLD Buy
+80.7% avg upside
21 analysts
$75.00
1.08% Upside
 +2.8% ·
EW
Edwards Lifesciences
 Jul 28, 2026 BUY Strong Buy
+12.6% avg upside
34 analysts
$110.00
23.95% Upside
 +7.2% ·
IART
Integra Lifesciences
 Jul 28, 2026 HOLD Buy
+151.5% avg upside
21 analysts
$19.00
9.05% Upside
 -13.5% ·
ISRG
Intuitive Surgical
 Jul 28, 2026 BUY Strong Buy
+28.2% avg upside
36 analysts
$500.00
33.22% Upside
 +4.7% ·
STAA
Staar Surgical
 Jul 28, 2026 SELL Hold
+46.8% avg upside
16 analysts
$20.00
12.37% Downside
 -6.4% ·
STE
Steris
 Jul 28, 2026 BUY Strong Buy
+6.1% avg upside
10 analysts
$275.00
20.50% Upside
 +1.0% ·
SYK
Stryker
 Jul 28, 2026 BUY Strong Buy
+9.2% avg upside
37 analysts
$400.00
19.05% Upside
 -2.2% ·
TFX
Teleflex
 Jul 28, 2026 HOLD Buy
+34.8% avg upside
20 analysts
$145.00
5.51% Upside
 +4.4% ·
GMED
Globus Medical
 Jul 28, 2026 HOLD Strong Buy
+14.6% avg upside
24 analysts
$82.00
2.33% Upside
 +0.9% ·
INSP
Inspire Medical Systems
 Jul 28, 2026 SELL Buy
+42.8% avg upside
21 analysts
$39.00
34.77% Downside
 +3.4% ·
SI
Shoulder Innovations, Inc.
 Jul 28, 2026 BUY Strong Buy
-2.8% avg upside
5 analysts
$27.00
20.51% Upside
 -6.2% ·
MMED
MiniMed Group, Inc.
 Jul 28, 2026 BUY Strong Buy
+18.4% avg upside
14 analysts
$25.00
34.42% Upside
 +2.9% ·
CH:ALC
Alcon
 Mar 11, 2026 HOLD Buy
+25.4% avg upside
35 analysts
$64.50
14.38% Upside
 -8.5% ·
MDLN
Medline
 Feb 25, 2026 BUY Strong Buy
+38.9% avg upside
27 analysts
$48.00
36.63% Upside
 -26.9% ·
TNDM
Tandem Diabetes Care
 Feb 20, 2026 HOLD Buy
+72.2% avg upside
29 analysts
$23.00
22.21% Upside
 -20.8% ·
HTFL
HeartFlow, Inc.
 Feb 17, 2026 HOLD Strong Buy
+33.9% avg upside
9 analysts
$35.00
29.06% Upside
 +29.4% ·
DXCM
Dexcom
 Feb 13, 2026 BUY Strong Buy
+26.2% avg upside
32 analysts
$75.00
9.73% Downside
 +21.0% ·
GEHC
GE Healthcare Technologies Inc
 Feb 05, 2026 HOLD Strong Buy
+17.0% avg upside
22 analysts
$85.00
21.68% Upside
 -12.7% ·
IRTC
Irhythm Technologies
 Dec 02, 2025 BUY Strong Buy
+32.2% avg upside
20 analysts
$205.00
63.64% Upside
 -29.5% ·
CRL
Charles River Labs
 Nov 11, 2025 HOLD Strong Buy
-12.8% avg upside
35 analysts
$185.00
28.34% Downside
 +50.7% ·
NTRA
Natera
 Nov 11, 2025 BUY Strong Buy
+0.6% avg upside
26 analysts
$220.00
16.68% Downside
 +55.8% ·
PEN
Penumbra
 Nov 06, 2025 HOLD Buy
+1.9% avg upside
23 analysts
$266.00
18.17% Downside
 +22.7% ·
TMO
Thermo Fisher
 Oct 28, 2025 BUY Strong Buy
+4.3% avg upside
38 analysts
$656.00
14.23% Upside
 +1.6% ·
TEM
Tempus AI, Inc. Class A
 Aug 12, 2025 BUY Buy
+41.5% avg upside
21 analysts
$68.00
47.81% Upside
 -21.5% ·
AVTR
Avantor
 Aug 04, 2025 HOLD Buy
+17.3% avg upside
26 analysts
$12.00
8.67% Downside
 +21.1% ·
IQV
IQVIA Holdings
 Jul 23, 2025 BUY Strong Buy
+4.1% avg upside
39 analysts
$220.00
3.97% Downside
 +6.7% ·
ORGO
Organogenesis Holdings
 May 27, 2025 HOLD Strong Buy
+384.5% avg upside
8 analysts
$6.00
154.23% Upside
 -10.4% ·
RBOT
Vicarious Surgical
 Jun 13, 2024 HOLD Buy
+18459.2% avg upside
6 analysts
$18.00
28025.08% Upside
 -15.7% ·
STVN
Stevanato Group
 Aug 24, 2023 HOLD Strong Buy
+35.3% avg upside
13 analysts
$34.00
69.04% Upside
 -41.1% ·
PHG
Koninklijke Philips
 Oct 04, 2022 HOLD Buy
+37.6% avg upside
13 analysts
$16.27
38.21% Downside
 +19.0% ·
GB:SN
Smith & Nephew
 Feb 22, 2022 BUY Buy
+1249.2% avg upside
16 analysts
$1473.00
34.12% Upside
 -3.8% ·
NL:PHIA
Koninklijke Philips N.V.
 Jul 28, 2021 HOLD Buy
+32.4% avg upside
21 analysts
$45.00
95.99% Upside
 -45.8% ·
DE:FRE
Fresenius SE & Co. KGaA
 Dec 03, 2020 HOLD Strong Buy
+8.8% avg upside
20 analysts
$42.00
10.11% Downside
 -9.3% ·
CH:LONN
Lonza Group Ltd
 Jan 31, 2019 HOLD Strong Buy
+13.8% avg upside
21 analysts
$267.00
52.92% Downside
 +48.9% ·
FMS
Fresenius Medical Care
 Jul 09, 2018 BUY Hold
+70.0% avg upside
15 analysts
 — -22.5% ·
DVA
DaVita
 Dec 11, 2017 BUY Buy
-8.5% avg upside
17 analysts
 — -17.2% ·
🔒 48 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Patrick Wood — Frequently Asked Questions
How accurate are Patrick Wood's stock ratings?
Based on the calls 13Foresight could measure, about 40% of Patrick's ratings were profitable over a one-year hold, with an average return of -3.8% per rating, or -12.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Patrick ranked on 13Foresight?
Patrick Wood is currently ranked #2823 with a 1-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Patrick cover?
Patrick most recently has ratings on PODD, SOLV, RXST, SGHT, ZBH, ATEC, PRCT, TMDX, SIBN, GKOS, BLCO, BSX and 41 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.